Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Rang in aandelen
#3624
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Aandeelprijs
$3.71
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$4.69B
Verandering (1 dag)
2.44%
Verandering (1 jaar)
-52.25%
Land
CN
Handel Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Categorie
Healthcare
P/S-ratio voor Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
P/S-ratio op October 2026 TTM: 15.67
Volgens de meest recente financiële rapporten en aandelenkoers van Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is de huidige P/S-ratio (TTM) 15.67. Eind 2023 had het bedrijf een P/S-ratio van 17.18.
P/S-ratiohistoriek voor Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. van 2013 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 15.67 | -62.38% |
| 2024 | 41.67 | 142.53% |
| 2023 | 17.18 | 69.95% |
| 2022 | 10.11 | -48.04% |
| 2021 | 19.46 | -35.13% |
| 2020 | 29.99 | 775.33% |
| 2019 | 3.43 | -14.52% |
| 2018 | 4.01 | 1.37% |
| 2017 | 3.95 | -11.91% |
| 2016 | 4.49 | -19.44% |
| 2015 | 5.57 | -11.75% |
| 2014 | 6.31 | -13.45% |
| 2013 | 7.30 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | -36.06% |
US
|
|
| 40.55 | 158.70% |
US
|
|
| 3.96 | -74.73% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -35.27% |
NL
|
